← board
MRVI
distress 1/10 · well-funded / low risk$7.27+2%today0% from 52w high
Revenue
$66M
Liquidity
$166M
Runway
4.2 yrs
Shares 1y
—
Price & events
+89.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
+2.4%
1D
+2.5%
1W
+35.4%
1M
+110.7%
3M
+96.0%
6M
+177.5%
1Y
-12.8%
2Y
-82.7%
5Y
-73.6%
All
Overview
- Volume
- 220.03K
- 52 Week Range
- $2.02 – $7.27
- Float Shares
- 101.17M
- Short %
- 7.09%
- % Held by Insiders
- 13.80%
- % Held by Institutions
- 88.19%
- RVOL
- 0.07x
- Beta
- 0.65
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-08-06earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $6 (-19% upside) · 5 analysts
- 2026-05-08Wells FargoOverweight
- 2025-12-15Wells FargoOverweight
- 2025-08-12RBC CapitalOutperform
- 2025-08-12Craig-HallumBuy
- 2025-05-13Craig-HallumBuy
- 2025-05-13BairdNeutral
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.